Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tryptophan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL27753251 | 1.00 | KDM4E (0.60) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL5605980 | 0.95 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL17889024 | 0.95 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL5605972 | 0.95 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL28813398 | 0.93 | KDM4E (0.61) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL28317266 | 0.93 | KDM4E (0.53) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL1833542 | 0.92 | KDM4E (0.63) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL1833538 | 0.92 | KDM4E (0.63) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL17686593 | 0.92 | KMT2A (0.71) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL28317265 | 0.92 | KMT2A (0.71) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101500594-A | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity | SIRION THERAPEUTICS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | KDM4E 4388/4885MAPT 1818/4885KMT2A 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.